Lilly Provides Update on Next Steps for Solanezumab

             Lilly Provides Update on Next Steps for Solanezumab

PR Newswire

INDIANAPOLIS, Dec. 12, 2012

INDIANAPOLIS, Dec. 12, 2012 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY)
today provided an update on the next steps planned for solanezumab, its Phase
3 monoclonal antibody being studied as a potential therapy for patients with
mild Alzheimer's disease. Following discussions with regulators in the U.S.,
Europe and Canada, Lilly plans to conduct an additional Phase 3 study of
solanezumab in patients with mild Alzheimer's disease. Additional details,
including study design and length, are still being determined. Lilly expects
to initiate this study no later than Q3 2013.

Based on recent meetings with the U.S. Food and Drug Administration (FDA),
Lilly does not intend to submit a Biologics License Application (BLA) at this
time in the U.S. based solely on the existing analyses of data from the
EXPEDITION studies. Lilly will continue to analyze and discuss the data from
the two, Phase 3, double-blind, placebo-controlled solanezumab EXPEDITION
studies with regulators globally to determine the regulatory paths forward in
different regions. It is possible that different courses of action could be
taken in different jurisdictions.

Independent analyses of the Phase 3 solanezumab EXPEDITION data were conducted
by the Alzheimer's Disease Cooperative Study (ADCS), an academic research
consortium, and presented at the annual meeting of the American Neurological
Association (ANA) on Oct. 8, 2012, and at the Clinical Trial on Alzheimer's
Disease (CTAD) meeting on Oct. 29, 2012.

"Based on both the independent analyses by the ADCS, as well as our own," said
Eric Siemers, senior medical director of Lilly's Alzheimer's disease team, "we
believe the results demonstrating a slowing of cognitive decline in patients
with mild Alzheimer's disease treated with solanezumab are the first data from
Phase 3 clinical trials that support the amyloid hypothesis."

"We remain encouraged and excited by the solanezumab data," said David Ricks,
senior vice president and president, Lilly Bio-Medicines. "We are committed to
working with the FDA and other regulatory authorities to bring solanezumab to
the millions of patients and caregivers suffering from this devastating
disease who urgently need this potential treatment."

About solanezumab
Solanezumab is a Phase 3, monoclonal antibody that binds to soluble monomeric
forms of amyloid-beta after it is produced, allowing it to be cleared before
it clumps together to form beta-amyloid plaques.

About the EXPEDITION Trials
The EXPEDITION trials consisted of two Phase 3, double-blind,
placebo-controlled solanezumab trials in patients with mild-to-moderate
Alzheimer's disease in 16 countries around the world. In both of the
EXPEDITION study protocols, mild Alzheimer's disease was defined as a baseline
Mini-Mental Status Examination (MMSE) score of 20 to 26 and moderate
Alzheimer's disease was defined as a baseline MMSE score of 16 to 19.

The designs of EXPEDITION1 and EXPEDITION2 were the same. Patients aged 55
years or older were eligible to enroll in these studies; EXPEDITION1 enrolled
1,012 patients and EXPEDITION2 enrolled 1,040 patients. Patients received
either 400mg of solanezumab infused intravenously (IV) or placebo every four
weeks for approximately 18 months. Both EXPEDITION trials allowed patients to
remain on stable standard of care (defined as their existing treatment
regimen) during these studies. More than 85 percent of the patients in these
trials were taking an acetycholinesterase inhibitor and / or memantine.

While primary endpoints, both cognitive and functional, were not met in the
two Phase 3, double-blind, placebo-controlled solanezumab EXPEDITION trials in
patients with mild-to-moderate Alzheimer's disease, a pre-specified secondary
analysis of pooled data in patients with mild Alzheimer's disease showed a
statistically significant slowing of cognitive decline. This finding
represented a 34 percent reduction in decline. Over the 18 months of the
EXPEDITION studies, the difference between patients treated with solanezumab
versus placebo increased at a relatively constant rate over time.

In the pooled analyses of the EXPEDITION studies, the only adverse event with
an incidence of at least 1 percent that occurred statistically significantly
more in the solanezumab group than in the placebo group was angina (1.1
percent versus 0.2 percent). The incidence of vasogenic edema (ARIA-E) was
approximately 1 percent, occurring in 11 patients treated with solanezumab and
5 patients on placebo, which was not statistically significant.

An ongoing, open-label extension study, EXPEDITION-EXT, is fully enrolled and
will continue as planned. 

About Alzheimer's disease
Alzheimer's disease, the most common form of dementia, causes progressive
decline in memory and other aspects of cognition.^1,2 Researchers do not know
exactly what causes Alzheimer's disease and there are currently no approved
treatments shown to slow the progression of this devastating disease, only
treatment options that reduce certain symptoms of the disease. ^ 1,3,4
Alzheimer's Disease International (ADI) estimates that there are currently
35.6 million people with dementia worldwide, with 7.7 million new cases each
year (which implies one new case every four seconds).^5 The number of people
affected is estimated to be over 115 million by 2050.^4 Estimates vary, but
experts suggest that as many as 5.4 million Americans may have Alzheimer's
disease.^3

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Ind., Lilly provides answers –
through medicines and information – for some of the world's most urgent
medical needs. Additional information about Lilly is available at
www.lilly.com. P-LLY

This press release contains certain forward-looking statements about
solanezumab. This release reflects Lilly's current beliefs; however, as with
any pharmaceutical product, there are substantial risks and uncertainties in
the process of development and commercialization. There is no guarantee that
future study results and patient experience will be consistent with study
findings to date, or that solanezumab will be approved as a product or will
prove to be commercially successful. For further discussion of these and other
risks and uncertainties, see Lilly's filings with the United States Securities
and Exchange Commission. Lilly undertakes no duty to update forward-looking
statements.

^1 National Institute of Neurological Disorders and Stroke. "Dementia: Hope
Through Research." Available at:
http://www.ninds.nih.gov/disorders/dementias/detail_dementia.htm#1908919213.
Accessed on August 13, 2012.

^2 Alzheimer's Association. "2012 Alzheimer's Disease Facts and Figures."
Available at: http://www.alz.org/downloads/facts_figures_2012.pdf. Accessed on
August 13, 2012.

^3 Robert P, Ferris S, Gauthier S, Ihl R, Winblad B, Tennigkeit F. Review of
Alzheimer's disease Scales: Is There a Need for a New Multi-domain Scale for
Therapy Evaluation in Medical Practice?. Alzheimer's Research & Therapy. 2010;
2(24): 1-13.

^4 Perrin, R., et al. "Multimodal techniques for diagnosis and prognosis of
Alzheimer's disease." Nature 2009 (461); 916-922.

^5 Alzheimer's Disease International. "Dementia Statistics." Available at:
http://www.alz.co.uk/research/statistics. Accessed on August 13, 2012.

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)

SOURCE Eli Lilly and Company

Contact: Stefanie Prodouz, +1-317-224-5331, prodouzs@lilly.com (Media); Philip
Johnson, +1-317-655-6874, johnson_philip_l@lilly.com (Investors)
 
Press spacebar to pause and continue. Press esc to stop.